Quantcast
Home > Quotes > INVA

Innoviva, Inc. Common Stock (INVA) Quote & Summary Data

INVA 
$13.99
*  
0.09
0.64%
Get INVA Alerts
*Delayed - data as of Aug. 17, 2018  -  Find a broker to begin trading INVA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
10.5
Today's High / Low
$ 14.15 / $ 13.87
Share Volume
395,862
50 Day Avg. Daily Volume
807,243
Previous Close
$ 14.08
52 Week High / Low
$ 17.99 / $ 11.47
Market Cap
1,420,093,353
P/E Ratio
9.92
Forward P/E (1y)
7.69
Earnings Per Share (EPS)
$ 1.41
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.75

Intraday Chart

Shares Traded

Share Volume:
395,862
50 Day Avg. Daily Volume:
807,243

P/E Ratio

P/E Ratio:
9.92
Forward P/E (1y):
7.69
Earnings Per Share (EPS):
$ 1.41

Trading Range

The current last sale of $13.99 is 21.97% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 14.15 $ 17.99
 Low: $ 13.87 $ 11.47

ETFs with INVA as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
1.11% SPDR S&P Pharmaceuticals ETF (XPH) +6.90 (16.53%)
1.01% iShares U.S. Pharmaceutical ETF (IHE) +20.98 (14.36%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Innoviva, Inc. ("Innoviva", the "Company", the "Registrant" or "we" and other similar pronouns) is focused on bringing compelling medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals to maximize the potential of its respiratory assets partnered with Glaxo Group Limited ("GSK"), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, "FF/VI"),ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, "UMEC/VI") and TRELEGY® ELLIPTA® (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist ("LABA") Collaboration Agreement, we are entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion and royalties from sales of ANORO(TM) ELLIPTA(TM) tier upward at a range from 6.5% to 10%.  ... More ...  


Risk Grade

Where does INVA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 14.07
Open Date:
Aug. 17, 2018
Close Price:
$ 13.99
Close Date:
Aug. 17, 2018

Consensus Recommendation

Analyst Info